Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAY D PAGE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1669422143
CMS profile
166358
Location
WEATHERFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$17,237.46

149 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $12,433.00 7
Food and Beverage $4,634.48 140
Education $169.98 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $3,802.19 3
ABBVIE INC. $3,375.00 1
Janssen Biotech, Inc. $2,533.46 6
Puma Biotechnology, Inc. $2,288.21 8
Regeneron Pharmaceuticals, Inc. $1,208.00 3
Daiichi Sankyo Inc. $489.66 9
Novartis Pharmaceuticals Corporation $351.99 8
Amgen Inc. $312.86 8
E.R. Squibb & Sons, L.L.C. $232.52 11
Gilead Sciences, Inc. $178.95 4
Genmab U.S., Inc. $152.91 4
Takeda Pharmaceuticals U.S.A., Inc. $150.31 4
Seagen Inc. $141.60 6
Bayer Healthcare Pharmaceuticals Inc. $136.98 2
AstraZeneca Pharmaceuticals LP $133.96 8
Celgene Corporation $128.36 7
INTUITIVE SURGICAL, INC. $125.00 1
Stemline Therapeutics Inc. $119.95 1
Merck Sharp & Dohme LLC $117.54 5
Spectrum Pharmaceuticals Inc. $113.88 2
Exelixis Inc. $106.24 2
Incyte Corporation $91.01 5
PFIZER INC. $88.81 5
Eisai Inc. $78.41 4
Immunocore Limited $71.69 1
Boehringer Ingelheim Pharmaceuticals, Inc. $63.79 2
Kite Pharma, Inc. $55.71 2
Lilly USA, LLC $49.86 3
Ipsen Biopharmaceuticals, Inc $48.97 1
GENZYME CORPORATION $44.73 2
PharmaEssentia USA Corporation $33.71 1
Genentech USA, Inc. $32.81 2
Adaptive Biotechnologies Corporation $29.60 1
EMD Serono, Inc. $25.88 1
Pharmacyclics LLC, An AbbVie Company $25.48 1
Regeneron Healthcare Solutions, Inc. $24.79 1
ARRAY BIOPHARMA INC $22.84 1
MorphoSys, US Inc. $22.68 1
Foundation Medicine, Inc. $21.60 1
BeiGene USA, Inc. $20.93 1
Acrotech Biopharma Inc. $20.89 1
Sun Pharmaceutical Industries Inc. $20.55 1
Karyopharm Therapeutics Inc. $20.36 1
Blueprint Medicines Corporation $20.14 1
GlaxoSmithKline, LLC. $19.65 1
Organon LLC $17.84 1
Rigel Pharmaceuticals, Inc. $16.65 1
SOBI, INC $16.64 1
TAIHO ONCOLOGY, INC. $16.40 1
Deciphera Pharmaceuticals Inc. $15.47 1

Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAY D PAGE

NPI 1669422143 · CMS profile ID 166358

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WEATHERFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669422143?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAY D PAGE, NPI 1669422143, CMS profile ID 166358. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669422143?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RAY D PAGE, NPI 1669422143, CMS profile ID 166358. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669422143?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RAY D PAGE, NPI 1669422143, CMS profile ID 166358, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1669422143?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

149 matching records · $17,237.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 149 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–149 of 149.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $119.5105/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000530025 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $32.0605/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996580887 CMS
Organon LLC $17.8405/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046958833 CMS
Janssen Biotech, Inc. $22.9304/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988554355 CMS
Adaptive Biotechnologies Corporation $29.6004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022978985 CMS
Eisai Inc. $16.0204/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023328797 CMS
Janssen Biotech, Inc. $13.6004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988554349 CMS
E.R. Squibb & Sons, L.L.C. $20.6704/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014859545 CMS
Foundation Medicine, Inc. $21.6004/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058792237 CMS
Seagen Inc. $20.2504/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995733985 CMS
Astellas Pharma US Inc $23.4703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034022345 CMS
E.R. Squibb & Sons, L.L.C. $111.8503/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014859517 CMS
E.R. Squibb & Sons, L.L.C. $16.2003/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014859527 CMS
E.R. Squibb & Sons, L.L.C. $1.8203/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014859537 CMS
Rigel Pharmaceuticals, Inc. $16.6503/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033400781 CMS
Puma Biotechnology, Inc. $11.1903/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059058803 CMS
Sun Pharmaceutical Industries Inc. $20.5503/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053949301 CMS
Daiichi Sankyo Inc. $17.6803/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006337251 CMS
Gilead Sciences, Inc. $124.2703/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025510171 CMS
Merck Sharp & Dohme LLC $22.9803/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048471761 CMS
ARRAY BIOPHARMA INC $22.8403/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050532111 CMS
Novartis Pharmaceuticals Corporation $19.5703/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992887845 CMS
Exelixis Inc. $21.2503/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044529481 CMS
Exelixis Inc. $84.9903/07/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044529199 CMS
Incyte Corporation $17.4603/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501795 CMS
Genmab U.S., Inc. $21.7603/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051347543 CMS
Daiichi Sankyo Inc. $21.5503/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006337201 CMS
Janssen Biotech, Inc. $150.0003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988554327 CMS
Janssen Biotech, Inc. $150.0003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988554333 CMS
Kite Pharma, Inc. $30.1702/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025272233 CMS
ABBVIE INC. $3,375.0002/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998060143 CMS
Novartis Pharmaceuticals Corporation $98.4102/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992887837 CMS
SOBI, INC $16.6402/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038073709 CMS
Celgene Corporation $25.5002/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014859469 CMS
AstraZeneca Pharmaceuticals LP $18.7202/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015873973 CMS
AstraZeneca Pharmaceuticals LP $16.2302/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011726773 CMS
Celgene Corporation $28.0902/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014859480 CMS
E.R. Squibb & Sons, L.L.C. $5.5002/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014859437 CMS
Janssen Biotech, Inc. $2,180.0002/07/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988554343 CMS
Daiichi Sankyo Inc. $19.4902/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006396807 CMS
Amgen Inc. $14.7301/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020068171 CMS
E.R. Squibb & Sons, L.L.C. $22.7501/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014859381 CMS
Lilly USA, LLC $17.7201/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032125941 CMS
Incyte Corporation $17.3701/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501747 CMS
Amgen Inc. $20.2701/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020660545 CMS
BeiGene USA, Inc. $20.9301/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051196401 CMS
Astellas Pharma US Inc $3,750.0001/04/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033853973 CMS
Seagen Inc. $24.8001/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995733847 CMS
Daiichi Sankyo Inc. $21.2901/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006382041 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,170.30 132
PY2020 $4,303.03 30
PY2021 $7,472.89 18
PY2022 $1,682.82 58
PY2023 $17,237.46 149
PY2024 $2,928.38 116
PY2025 $3,274.62 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $217,764.25 44
PY2024 Principal investigator $263,572.52 32
PY2023 Principal investigator $731,969.93 60
PY2022 Principal investigator $457,538.32 38
PY2021 Principal investigator $142,852.05 38
PY2020 Principal investigator $284,810.15 80
PY2019 Recipient $5,663.00 2
PY2019 Principal investigator $286,425.24 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,550.00 12/11/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240601424
Principal investigator 1 Eli Lilly and Company $2,082.00 12/09/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CONSULTANTS P A
CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1187885474
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 11/26/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 11/25/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184264345
Principal investigator 1 Incyte Corporation $120.00 11/24/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240601421
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 11/14/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132417
Principal investigator 1 Incyte Corporation $1,056.40 10/30/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240601417
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 10/29/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192183111
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 10/20/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183097
Principal investigator 1 GlaxoSmithKline, LLC. $1,400.00 10/09/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183073
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 10/09/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183093
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 09/26/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132450
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 08/26/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132423
Principal investigator 1 Eli Lilly and Company $478.00 07/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CONSULTANTS P A
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187887100
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,500.00 07/25/2025 Non-covered Recipient Entity
CENTER FOR CANCER AND BLOOD DISORDE
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190312341
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 07/24/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132438
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 06/23/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132461
Principal investigator 1 Incyte Corporation $750.00 05/22/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240601411
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 05/16/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132465
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 05/13/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192183106
Principal investigator 1 Incyte Corporation $240.00 05/08/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240601408
Principal investigator 1 Incyte Corporation $1,969.35 05/08/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240601414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 05/02/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.00 05/02/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,250.00 05/02/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,000.00 05/02/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191981
Principal investigator 1 Daiichi Sankyo Inc. $10,034.00 04/17/2025 Non-covered Recipient Entity
Oncology Hematology Consultants, Pa
DS1062-A-U301 No dispute reported 06/30/2026 1223375615
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 03/27/2025 Non-covered Recipient Entity
Oncology Hematology Consultants Pa
DS1062-A-U301 No dispute reported 06/30/2026 1223375607
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 03/21/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132456
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183079
Principal investigator 1 GlaxoSmithKline, LLC. $20,000.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183083
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183088
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183101
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183132
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183137
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183141
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183145
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 02/24/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192183149
Principal investigator 1 Incyte Corporation $528.20 02/20/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240601432
Principal investigator 1 Incyte Corporation $12,338.00 02/13/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240601428
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 02/04/2025 Non-covered Recipient Entity
ONEONCOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192132444
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,750.00 02/03/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185543815
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,000.00 01/29/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185543813
Principal investigator 1 AstraZeneca Pharmaceuticals LP $32,168.30 01/10/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 1185543811